UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1001-13
Program Prior Authorization/Notification
Medication Actimmune® (interferon gamma-1b)
P&T Approval Date 02/2013, 8/2014, 8/2015, 6/2016, 6/2017, 6/2018, 6/2019, 6/2020, 6/2021,
6/2022, 6/2023, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Actimmune (interferon gamma-1b) is indicated for reducing the frequency and severity of
serious infections associated with chronic granulomatous disease (CGD). It is also indicated
for delaying time to disease progression in patients with severe, malignant osteopetrosis
(SMO). The National Cancer Comprehensive Network (NCCN) recommends use of
Actimmune in mycosis fungoides (MF) and Sézary syndrome (SS).
Coverage Information:
Members will be required to meet the criteria below for coverage.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Actimmune will be approved based on both of the following criteria:
a. Patient has oncology diagnosis
-AND-
b. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Chronic Granulomatous Disease (CGD)
1. Authorization
a. Actimmune will be approved based on the following criterion:
(1) Diagnosis of chronic granulomatous disease
Authorization will be issued for 12 months.
© 2025 UnitedHealthcare Services, Inc.
1
2. Reauthorization
a. Actimmune will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Actimmune
Authorization will be issued for 12 months.
C. Osteopetrosis
1. Initial Authorization
a. Actimmune will be approved based on the following criterion:
(1) Diagnosis of severe, malignant osteopetrosis
Authorization will be issued for 12 months.
2. Reauthorization
a. Actimmune will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Actimmune
Authorization will be issued for 12 months.
D. Primary Cutaneous Lymphomas
1. Initial Authorization
a. Actimmune will be approved based on the following criterion:
(1) Patient has one of the following diagnoses:
(a) Mycosis fungoides (MF)
(b) Sézary syndrome (SS)
Authorization will be issued for 12 months.
2. Reauthorization
a. Actimmune will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Actimmune
Authorization will be issued for 12 months.
E. NCCN Recommended Regimens
© 2025 UnitedHealthcare Services, Inc.
2
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category
of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class
• Supply limits may apply.
4. References:
1. Actimmune [Package Insert]. Deerfield, IL: Horizon Therapeutics USA Inc.; December 2024.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
www.nccn.org. Accessed April 28, 2025.
Program Prior Authorization/Notification - Actimmune (interferon gamma-1b)
Change Control
8/2014 Annual review with no changes to Coverage Criteria. Updated formatting
and References.
8/2015 Annual review. Added oncology indication requirement to age 19 criteria.
Increased authorization and reauthorization from 6 months to 12 months
for all indications. Updated references.
6/2016 Annual review. Added reauthorization criteria for CGD. Updated
formatting and references.
6/2017 Annual review. Updated references.
6/2018 Annual review. Updated references.
6/2019 Annual review. Updated Non-Hodgkin’s Lymphoma to Primary
Cutaneous Lymphomas. Updated references.
6/2020 Annual review. Updated references.
6/2021 Annual review. No changes to coverage criteria. Updated background and
references.
6/2022 Annual review. No changes to coverage criteria. Updated references.
6/2023 Annual review. No changes to coverage criteria. Added state mandate
footnote. Updated reference.
6/2024 Annual review. No changes to coverage criteria.
6/2025 Annual review with no changes to coverage criteria. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3